Immune Complexes and the Risk of CVD in Type 1 Diabetes

Area of Science:

• Cardiovascular Research
• Diabetes Complications
• Immunology

Background:

• Type 1 diabetes (T1D) significantly increases cardiovascular disease (CVD) risk.
• Modified forms of low-density lipoprotein (LDL) are implicated in atherosclerosis.
• Circulating immune complexes (ICs) involving modified LDL may play a role in CVD pathogenesis.

Purpose of the Study:

• To investigate the association between modified LDL-ICs and CVD outcomes in T1D.
• To determine if specific modified LDL components within ICs predict CVD events.
• To assess the early predictive value of these biomarkers over a 25-year period.

Main Methods:

• Analysis of baseline levels of oxidized LDL (oxLDL), MDA-modified LDL (MDA-LDL), and advanced glycosylation-modified LDL (AGE-LDL) within circulating ICs.
• Assessment of associations with CVD outcomes including any CVD, major adverse cardiac and cerebrovascular events (MACCE), myocardial infarction (MI), and coronary artery disease.
• Statistical adjustments for age, HbA1c, and other cardiovascular risk factors, including LDL cholesterol.

Main Results:

• Baseline levels of oxLDL-IC, MDA-LDL-IC, and AGE-LDL-IC were associated with CVD outcomes in unadjusted models.
• oxLDL-IC and MDA-LDL-IC remained independently associated with CVD risk after adjusting for major risk factors.
• oxLDL-IC independently predicted MACCE and MI risk, even after comprehensive adjustments.
• These associations persisted over a 25-year follow-up period, indicating early predictive value.

Conclusions:

• Modified LDL-ICs, particularly oxLDL-IC and MDA-LDL-IC, are significant independent predictors of CVD outcomes in T1D.
• These biomarkers identify high-risk T1D patients years before clinical CVD manifestation.
• Modified LDL-ICs offer potential for early CVD risk stratification in T1D management.